Events

Quantifying Immunogenicity in Oncology and Virology

Speaker
Benjamin Greenbaum, PhD
Icahn School of Medicine at Mount Sinai
Location

Irving Cancer Research Center
1130 St. Nicholas Avenue
Room 116
New York, NY 10032

Benjamin Greenbaum, PhD, is assistant professor in the Departments of Medicine, Hematology, and Medical Oncology, Oncological Sciences,and Pathology at the Tisch Cancer Institute at Mount Sinai. As part of the Program for Mathematical Genomics Seminar Series, he will deliver the talk, "Quantifying Immunogenicity in Oncology and Virology", followed by a Q+A.

Immune recognition is a critical determinant of pathogen evolution, and avoidance of immune detection is a critical issue for a tumor. The later can in some cases be exploited for cancer immunotherapies. A key mathematical issue that has emerged in both immunology oncology is therefore the extent to which we can quantify the features that make a molecule immunogenic and which of those features can be a fitness determinant either endogenously or under therapy. We will discuss our recent work on this problem where we have learned from the genome evolution of tumors and viruses, and its implications for cancer immunotherapies.

Event Series Name
Program for Mathematical Genomics Seminar
Host(s)
Dr. Raul Rabadan

Add to Calendar
06-18-2019 10:30:00
06-18-2019 11:45:00
15
Benjamin Greenbaum, PhD (Icahn School of Medicine)
Benjamin Greenbaum, PhD, is assistant professor in the Departments of Medicine, Hematology, and Medical Oncology, Oncological Sciences,and Pathology at the Tisch Cancer Institute at Mount Sinai. As part of the Program for Mathematical Genomics Seminar Series, he will deliver the talk, "Quantifying Immunogenicity in Oncology and Virology", followed by a Q+A.

Immune recognition is a critical determinant of pathogen evolution, and avoidance of immune detection is a critical issue for a tumor. The later can in some cases be exploited for cancer immunotherapies. A key mathematical issue that has emerged in both immunology oncology is therefore the extent to which we can quantify the features that make a molecule immunogenic and which of those features can be a fitness determinant either endogenously or under therapy. We will discuss our recent work on this problem where we have learned from the genome evolution of tumors and viruses, and its implications for cancer immunotherapies.
Florence Irving Auditorium ICRC, 1st Floor
false
MM/DD/YYYY